These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35411248)

  • 1. PIK-75 overcomes venetoclax resistance
    Huang S; Liu Y; Chen Z; Wang M; Jiang VC
    Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
    Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
    EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
    Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
    Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma.
    Granau AM; Andersen PA; Jakobsen T; Taouxi K; Dalila N; Mogensen JB; Kristensen LS; Grønbæk K; Dimopoulos K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.
    Jiang V; Lee W; Zhang T; Jordan A; Yan F; Cai Q; McIntosh J; Vargas J; Liu Y; Wang M
    Biomark Res; 2024 Jun; 12(1):62. PubMed ID: 38886769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.
    Li Y; Lee HH; Jiang VC; Che Y; McIntosh J; Jordan A; Vargas J; Zhang T; Yan F; Simmons ME; Wang W; Nie L; Yao Y; Jain P; Wang M; Liu Y
    Cell Death Dis; 2023 Nov; 14(11):714. PubMed ID: 37919300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
    Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
    Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Thus YJ; Eldering E; Kater AP; Spaargaren M
    Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.
    Zhang Y; Lu P; Zhou Y; Zhang L
    PeerJ; 2021; 9():e12571. PubMed ID: 35003920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Guan J; Huang D; Yakimchuk K; Okret S
    Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
    Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
    Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.